I believe that I can categorize myself as a semi-retired, occasional investor, who is interested in developing my expertise in this field. My background is in real estate development. I remain active on a limited scale in that arena. I find myself interested in the Dividend growth area of investing. I am as interested in the growth of stocks that I invest in as I am the dividends and their related growth. I am interested in learning more about REITS and MLP investment.
MTR Investors Group goal is to provide the best Covered / Naked, Credit Spread, and Iron Condor Option Screeer on the web. Screen over 3,100 stocks and over 270,000 options in seconds to find the best possible trades!
Option writers use our screener to find options trades that have the highest probability of expiring worthless.
Attempting to find profitable option trades on over 3,100 stocks and over 250,000 options, and millions of Credit Spread and Iron Condor combinations is a huge effort. The MTR option screener simplifies that process and will discover trades that otherwise would be missed.
This is an end of day screening service. It is geared toward traders that look for trading opportunities after hours to prepare for the next trading day.
We use Stock Market Scout (SMS) as a model to indicate allocating cash to an index ETF (such as SPY) by going long on Green, cash on Yellow, short on Red (or stay in cash). This is not a recommendation to buy or sell SPY.
We are proud to offer powerful tools for free or at price point that allows any investor to have an edge.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.